D. Western Therapeutics Institute Inc (4576):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:D. Western Therapeutics Institute Inc (4576) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8019
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
D. Western Therapeutics Institute Inc (DWTI) is a pharmaceutical product s developer. The company offers ophthalmic solution, WP-1303, H-1337, K-134 and DW-1002. It discovers and develops drugs for glaucoma. DWTI’s ophthalmic solution treats glaucoma and ocular hypertension treatment and arteriosclerosis obliterans. The company’s glanatek is an opthalmic solution with composition of ripasudil hydrochloride hydrate developed for the treatment of glaucoma through its intraocular pressure lowering action. It offers licensing out and promotion of development. The company operates in Japan, The US, Korea and Europe. DWTI is headquartered in Nagoya, Japan.

D. Western Therapeutics Institute Inc (4576) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
D. Western Therapeutics Institute Inc, Medical Devices Deals, 2012 to YTD 2018 9
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
D.Western Therapeutics Institute Acquires Ophthalmic Surgical Adjuvant Business from Healios for USD11 Million 12
Partnerships 13
D. Western Therapeutics Institute Enters into Option Agreement with Allysta Pharma 13
Glaukos Enters into Development Agreement with D. Western Therapeutics Institute 14
Edit Force Enters into Research Agreement with Japan Innovative Therapeutics 15
D.Western Therapeutics Institute Enters into Research Agreement with Chiba University 16
D.Western Therapeutics Institute Enters into Research Agreement with University of Toyama 17
D. Western Therapeutics Institute Enters into Strategic Agreement with Allysta Pharma 18
Licensing Agreements 19
Japan Innovative Therapeutics Enters into Licensing Agreement with Institute of Neuroimmunology 19
D.Western Therapeutics Institute Plans to Enter into Option Agreement for H-1129 20
Wakamoto Pharma Enters into Licensing Agreement with D. Western Therapeutics Institute 21
D.Western Therapeutics Institute Enters into Licensing Agreement with Doshisha University 22
Equity Offering 23
D.Western Therapeutics Institute Raises USD2 Million in Private Placement of Shares, upon Exercise of Warrants 23
D. Western Therapeutics Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 24
D. Western Therapeutics Raises USD2.3 Million in Private Placement of Shares upon Exercise of Warrants 25
D. Western Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 26
Acquisition 27
ROHTO Pharma Acquires 59.43% Stake in Japan Innovative Therapeutics for USD44 Million 27
D. Western Therapeutics Institute Inc – Key Competitors 28
D. Western Therapeutics Institute Inc – Key Employees 29
D. Western Therapeutics Institute Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
D. Western Therapeutics Institute Inc, Deals By Therapy Area, 2012 to YTD 2018 8
D. Western Therapeutics Institute Inc, Medical Devices Deals, 2012 to YTD 2018 9
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
D.Western Therapeutics Institute Acquires Ophthalmic Surgical Adjuvant Business from Healios for USD11 Million 12
D. Western Therapeutics Institute Enters into Option Agreement with Allysta Pharma 13
Glaukos Enters into Development Agreement with D. Western Therapeutics Institute 14
Edit Force Enters into Research Agreement with Japan Innovative Therapeutics 15
D.Western Therapeutics Institute Enters into Research Agreement with Chiba University 16
D.Western Therapeutics Institute Enters into Research Agreement with University of Toyama 17
D. Western Therapeutics Institute Enters into Strategic Agreement with Allysta Pharma 18
Japan Innovative Therapeutics Enters into Licensing Agreement with Institute of Neuroimmunology 19
D.Western Therapeutics Institute Plans to Enter into Option Agreement for H-1129 20
Wakamoto Pharma Enters into Licensing Agreement with D. Western Therapeutics Institute 21
D.Western Therapeutics Institute Enters into Licensing Agreement with Doshisha University 22
D.Western Therapeutics Institute Raises USD2 Million in Private Placement of Shares, upon Exercise of Warrants 23
D. Western Therapeutics Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 24
D. Western Therapeutics Raises USD2.3 Million in Private Placement of Shares upon Exercise of Warrants 25
D. Western Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 26
ROHTO Pharma Acquires 59.43% Stake in Japan Innovative Therapeutics for USD44 Million 27
D. Western Therapeutics Institute Inc, Key Competitors 28
D. Western Therapeutics Institute Inc, Key Employees 29
D. Western Therapeutics Institute Inc, Subsidiaries 30

List of Figures
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
D. Western Therapeutics Institute Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[D. Western Therapeutics Institute Inc (4576):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Laboratory Corporation of America Holdings:企業の戦略・SWOT・財務分析
    Laboratory Corporation of America Holdings - Strategy, SWOT and Corporate Finance Report Summary Laboratory Corporation of America Holdings - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • LIC of India:企業の戦略・SWOT・財務情報
    LIC of India - Strategy, SWOT and Corporate Finance Report Summary LIC of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Teledyne Technologies Incorporated (TDY):企業の財務・戦略的SWOT分析
    Teledyne Technologies Incorporated (TDY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • BDO International Limited:企業の戦略・SWOT・財務分析
    BDO International Limited - Strategy, SWOT and Corporate Finance Report Summary BDO International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Marriott Vacations Worldwide Corporation:企業の戦略・SWOT・財務情報
    Marriott Vacations Worldwide Corporation - Strategy, SWOT and Corporate Finance Report Summary Marriott Vacations Worldwide Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Next Plc:企業の戦略・SWOT・財務情報
    Next Plc - Strategy, SWOT and Corporate Finance Report Summary Next Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • American Equity Investment Life Holding Company:企業の戦略・SWOT・財務情報
    American Equity Investment Life Holding Company - Strategy, SWOT and Corporate Finance Report Summary American Equity Investment Life Holding Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • BioLamina AB:製薬・医療:M&Aディール及び事業提携情報
    Summary BioLamina AB (BioLamina) is a biotechnology company that focuses on the development, manufacture and distribution of cell culture reagents intended for culturing primary cells. The company offers a wide portfolio of chemically defined and xeno-free laminin proteins. Its product portfolio inc …
  • China Foods Ltd:企業の戦略・SWOT・財務分析
    China Foods Ltd - Strategy, SWOT and Corporate Finance Report Summary China Foods Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Commonwealth Bank of Australia:企業の戦略・SWOT・財務情報
    Commonwealth Bank of Australia - Strategy, SWOT and Corporate Finance Report Summary Commonwealth Bank of Australia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • GFI Informatique:企業の戦略・SWOT・財務分析
    GFI Informatique - Strategy, SWOT and Corporate Finance Report Summary GFI Informatique - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • CARBO Ceramics Inc (CRR):企業の財務・戦略的SWOT分析
    CARBO Ceramics Inc (CRR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • National Institute of Neurological Disorders and Stroke-製薬・医療分野:企業M&A・提携分析
    Summary National Institute of Neurological Disorders and Stroke (NINDS), a subsidiary of National Institutes of Health is a healthcare research institute that conducts and supports research on brain and nervous system disorders. The institute’s clinical research areas include Alzheimer’s disease, br …
  • Brazil Fast Food Corp.:企業の戦略・SWOT・財務分析
    Brazil Fast Food Corp. - Strategy, SWOT and Corporate Finance Report Summary Brazil Fast Food Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Jiangsu Expressway Co Ltd (600377):企業の財務・戦略的SWOT分析
    Summary Jiangsu Expressway Co Ltd (Jiangsu Expressway) is a highway development company that offers services in investment, construction, operation and management of toll expressways within Jiangsu province. The company offers services such as geographical services, service area development, express …
  • Sibur Holding:企業の戦略的SWOT分析
    Sibur Holding - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Becton, Dickinson:企業のM&A・事業提携・投資動向
    Becton, Dickinson - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Becton, Dickinson Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Gunvor Group Limited:石油・ガス:M&Aディール及び事業提携情報
    Summary Gunvor Group Limited (Gunvor) is a vertically integrated energy trading company. It is one of the global traders of physical crude oil; refined products and energy; and metals and bulk materials. The company provides integrated trading products and logistics service to connect upstream suppl …
  • Southern California Edison Co:電力:M&Aディール及び事業提携情報
    Summary Southern California Edison Co (SCE), a subsidiary of Edison International, is an electric utility that generates, procures, sources, and supplies electricity. The company generates electricity from various sources including natural gas, hydro, nuclear, solar, and oil and gas. It sources rema …
  • STMicroelectronics N.V. (STM)-エネルギー分野:企業M&A・提携分析
    Summary STMicroelectronics N.V. (ST) is a microelectronics company that designs, develops, manufactures, and markets a broad range of products for analog, digital, and mixed-signal applications. It offers standard commodity components, custom devices and semi-custom devices, application-specific int …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆